Innovation

VARIOUS PMST1 MUTANTS AND THE SYNTHESIS OF A LIBRARY OF SIALYL LEWIS X CONTAINING DIFFERENT SIALIC ACID FORMS

University of California System: University of California, Davis - UC Davis
posted on 12/09/2011

Researchers at the University of California, Davis have developed a new method of obtaining a library of sialyl Lewis x and other sialosides containing different sialic acid forms. This method utilizes engineered mutants of sialyltransferase PmST1. These novel mutants show lower donor hydrolysis activity and/or sialidase activity without compromising the sialyltransferase activity.

Suggested Uses

Useful for:

  • PmST1 mutants (E271F, R313Y, and E271F/ R313Y): Optimizing sialyltransferase-catalyzed reactions by lowering sialidase activity
  • Creating a library of sialyl Lewis x that contains different sialic acid forms efficiently

Advantages

  • Enzymatic sialylation avoids tedious protection and deprotection processes required by chemical sialylation
  • More efficient approach to generating a library of sialyl Lewis x that contains different sialic acid forms
    • PmST1_M144D: easy to obtain, robust sialyltransferase, efficient
    • Decreased sialidase activity
  • PmST1 mutants (E271F, R313Y, and E271F/ R313Y):
    • Powerful sialyltransferases with decreased sialidase activity
    • Good for sialylation when the reactions are not practical to monitor


Innovation Details
 

Detailed Description

Sialic acids are a family of monosaccharides that are commonly found as terminal residues on cell surface glycoproteins/glycolipids of higher animals. They have a vital role in cellular communication and recognition.

 

To a much lesser degree, they are also found in microorganisms and their presence is often linked with pathogenicity. To study the importance of various sialic acid forms in nature, an efficient synthetic approach is required to obtain a library of sialyl Lewis x and other sialosides containing different sialic acid forms.

 

UC Davis researchers have discovered a novel method of creating a library of sialyl Lewis x that contains different sialic acid forms using a chemoenzymatic approach. This new method proceeds through the addition of a sialic acid analog to a fucosylated Lewis x structure. The Pasteurella multocida alpha-2-3-sialyltransferase (PmST1) was engineered to tolerate the Lewis x as its substrate. The resulting PmST1 mutant (PmST1_M144D) was successfully utilized to synthesize the library of interest.

 

UC Davis researchers also generated three other engineered mutant forms of PmST1: E271F, R313Y, and E271F/ R313Y. The three resulting mutants (E271F, R313Y, and E271F/ R313Y) all showed lowered sialidase activity without compromising the desired sialyltransferase activity. To summarize, the use of these novel PmST1 mutants sheds new light on glycosyltransferase-catalyzed reactions, provides a novel strategy to improve glycosyltransferase substrate promiscuity, and supplies novel catalysts for efficient synthesis of complex sialosides.

File Number: 22185 


IP Protection

Copyright: ©2011, The Regents of the University of California

License Online

This innovation currently is not available for online licensing. Please contact Madhu Sharma at University of California System: University of California, Davis - UC Davis for more information.

Request more info via email request more info
People

Case Manager:

Madhu Sharma Madhu Sharma

Innovations (33)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

8,815 members 16,688 innovations 159 organizations

Browse

William Garner, M.D., MPH - CEO of Urigen, N.A., Inc.

"The iBridge Network provides an important additional pathway for entrepreneurs to access university innovations that may otherwise have been lost. The transparency of this pathway between entrepreneurs..."  read more...